Subcutaneous Lecanemab Maintenance Dosing for Alzheimer’s Supported by New Data

By News Health
6 hours Ago

(MedPage Today) — TORONTO — An investigational subcutaneous autoinjector showed comparable efficacy and safety to the IV formulation of lecanemab (Leqembi) for maintenance treatment in early Alzheimer’s disease, researchers said here.
Continued…

Source link : https://www.medpagetoday.com/meetingcoverage/aaic/116807

Author :

Publish date : 2025-08-03 17:53:00

Copyright for syndicated content belongs to the linked Source.

Categories: Health News

Related Content

Atropine Drops for Vitreous Floaters Show Promise as Less Invasive Alternative

'I Can't Pee Like I Used to Pee': What We Heard This Week

Advice to Young Physicians: Avoid the Headhunters

Artists help Tamworth pupils and cancer centre users create murals

Combination Therapy for AMD Fails to Improve Vision Versus Single Drug

Questions Abound About Treating AMD, Geographic Atrophy at the Same Time